Literature DB >> 9561675

An immunosuppressive regimen using FTY720 combined with cyclosporin in canine kidney transplantation.

S Suzuki1, T Kakefuda, H Amemiya, K Chiba, Y Hoshino, T Kawaguchi, H Kataoka, F Rahman.   

Abstract

FTY720 induces apoptosis, specifically in lymphocytes, and prolongs allograft survival in rats and dogs. The purpose of this study was to define an effective range of FTY720 doses that could be combined with a suboptimal dose (10 mg/kg) of cyclosporin for canine kidney allograft recipients. The combination significantly prolonged allograft survival in all groups receiving FTY720 at a dose of 0.1, 0.3, 1.0, or 3.0 mg/kg. None of the recipients died due to notable side effects of the drug. In peripheral blood, the number of lymphocytes was extremely low, whereas the percentage of granulocytes increased during FTY720 administration. No significant difference in cyclosporin trough levels was observed between the cyclosporin-alone group and the combination groups. We conclude from the present study that FTY720 has a potent effect at an extremely low dose and a wide therapeutic window when combined with cyclosporin in canine kidney transplants.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9561675     DOI: 10.1007/s001470050111

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  7 in total

Review 1.  A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

Authors:  Jerold Chun; Volker Brinkmann
Journal:  Discov Med       Date:  2011-09       Impact factor: 2.970

Review 2.  Regulation of immunity by lysosphingolipids and their G protein-coupled receptors.

Authors:  Edward J Goetzl; Hugh Rosen
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 3.  The influence of sphingosine-1-phosphate receptor signaling on lymphocyte trafficking: how a bioactive lipid mediator grew up from an "immature" vascular maturation factor to a "mature" mediator of lymphocyte behavior and function.

Authors:  Michael D Davis; John H Kehrl
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

4.  Fingolimod: Lessons Learned and New Opportunities for Treating Multiple Sclerosis and Other Disorders.

Authors:  Jerold Chun; Yasuyuki Kihara; Deepa Jonnalagadda; Victoria A Blaho
Journal:  Annu Rev Pharmacol Toxicol       Date:  2019-01-06       Impact factor: 13.820

Review 5.  Sphingosine-1-Phosphate Metabolism and Signaling in Kidney Diseases.

Authors:  Yelena Drexler; Judith Molina; Alla Mitrofanova; Alessia Fornoni; Sandra Merscher
Journal:  J Am Soc Nephrol       Date:  2020-12-18       Impact factor: 14.978

6.  A Requirement of Protein Geranylgeranylation for Chemokine Receptor Signaling and Th17 Cell Function in an Animal Model of Multiple Sclerosis.

Authors:  Gregory Swan; Jia Geng; Eunchong Park; Quanquan Ding; John Zhou; Ciana Walcott; Junyi J Zhang; Hsin-I Huang; Gianna Elena Hammer; Donghai Wang
Journal:  Front Immunol       Date:  2021-03-22       Impact factor: 7.561

7.  Sphingosine 1-phosphate receptor 1 as a useful target for treatment of multiple sclerosis.

Authors:  Kenji Chiba; Kunitomo Adachi
Journal:  Pharmaceuticals (Basel)       Date:  2012-05-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.